(Q39822717)

14 September 2017

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo (English)

1 reference

14 September 2017

1 reference

12

1 reference

14 September 2017

Aran F Labrijn

1

0 references

Joep Killestein

7

object named as

Joep Killestein

1 reference

14 September 2017

Antonio Ortiz Buijsse

2

1 reference

14 September 2017

Ewald T J van den Bremer

3

1 reference

14 September 2017

Annemiek Y W Verwilligen

4

1 reference

14 September 2017

Wim K Bleeker

5

1 reference

14 September 2017

Susan J Thorpe

6

1 reference

14 September 2017

Chris H Polman

8

1 reference

14 September 2017

Rob C Aalberse

9

1 reference

14 September 2017

Janine Schuurman

10

1 reference

14 September 2017

Jan G J van de Winkel

11

1 reference

14 September 2017

language of work or name

1 reference

20 July 2009

1 reference

14 September 2017

1 reference

14 September 2017

27

1 reference

14 September 2017

767-771

1 reference

14 September 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt.1553

14 September 2017

0 references

cites work

Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNBT.1553

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNBT.1553

When binding is enough: nonactivating antibody formats.

21 January 2018

1 reference

12 December 2020

Intrachain disulfide bond in the core hinge region of human IgG4.

1 reference

12 December 2020

Immunology. Square-dancing antibodies

1 reference

12 December 2020

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

12 December 2020

A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody

1 reference

12 December 2020

The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds

1 reference

12 December 2020

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

12 December 2020

Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies

1 reference

12 December 2020

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

12 December 2020

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate

1 reference

12 December 2020

Isotype selection in antibody engineering

1 reference

12 December 2020

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

12 December 2020

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

1 reference

12 December 2020

Diverse IgG subclass responses to adeno-associated virus infection and vector administration

1 reference

12 December 2020

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

1 reference

12 December 2020

Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1

1 reference

12 December 2020

Immunosuppressive therapy in dermatology and PML.

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

12 December 2020

Subclass distribution of human myeloma proteins as determined with monoclonal antibodies

1 reference

12 December 2020

"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics

1 reference

12 December 2020

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/NBT.1553

1 reference

14 September 2017

1 reference